Eye fluid study seeks clues to why some macular degeneration patients Don't improve
NCT ID NCT03630562
First seen Mar 30, 2026 · Last updated May 01, 2026 · Updated 2 times
Summary
This study looked at proteins in the eye fluid of 100 people with age-related macular degeneration (AMD) to understand why some don't respond well to standard anti-VEGF injections. Researchers measured levels of growth-promoting proteins and inflammation markers at the start and after 3 months. The goal was to find patterns that could predict treatment response, not to test a new therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Pasteur 2 - Service d'Ophtalmologie
Nice, 06001, France
Conditions
Explore the condition pages connected to this study.